LETROZOL Amarox 2,5 mg Filmtabletten

Description

Indications

Early-stage breast cancer with estrogen receptor expression in postmenopausal women as adjuvant therapy; early-stage breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen as extended adjuvant therapy; advanced hormone-dependent breast cancer in postmenopausal women as first-line therapy; advanced breast cancer in postmenopausal women (natural or artificially induced) who have received prior anti-estrogen therapy; advanced breast cancer in postmenopausal women who have received prior anti-estrogen therapy.

Contraindications

• hormonal conditions characteristic of the reproductive period;
• pregnancy;
• lactation period (breastfeeding);
• childhood (efficacy and safety in children has not been established);
• hypersensitivity to the components of the drug.
• The drug should be used with caution in cases of lactase deficiency, lactase intolerance, glucose-galactose malabsorption syndrome.

There are no data on the use of letrozole in patients with a CK < 30 ml/min (the ratio of potential risk to expected treatment effect should be carefully considered before prescribing the drug to such patients).

Precautions

Some of the drug’s side effects, such as general weakness and dizziness, may affect the ability to perform potentially hazardous activities requiring increased concentration and rapid psychomotor responses. Patients should therefore exercise caution when driving and operating machinery.